ארצות הברית - אנגלית - NLM (National Library of Medicine)

mylan institutional llc - dimethyl sulfoxide (unii: yow8v9698h) (dimethyl sulfoxide - unii:yow8v9698h) - dimethyl sulfoxide 0.54 g in 1 ml - rimso-50® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. rimso-50® has not been approved as being safe and effective for any other indication. there is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract. none known. none known.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

zoetis inc. - dimethyl sulfoxide (unii: yow8v9698h) (dimethyl sulfoxide - unii:yow8v9698h) - dimethyl sulfoxide 90 g in 100 ml

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - trametinib dimethyl sulfoxide, quantity: 2.254 mg (equivalent: trametinib, qty 2 mg) - tablet, film coated - excipient ingredients: mannitol; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; sodium lauryl sulfate; hypromellose; titanium dioxide; polysorbate 80; iron oxide red; macrogol 400 - unresectable or metastatic melanoma,mekinist in combination with dabrafenib is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma.,mekinist as a monotherapy is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is intolerance to braf inhibitors or braf inhibitors cannot be used.,mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy (see section 5.1 clinical trials).,adjuvant treatment of melanoma,mekinist in combination with dabrafenib is indicated for the adjuvant treatment of patients with melanoma with a braf v600 mutation and involvement of the lymph node(s), following complete resection.,anaplastic thyroid cancer (atc),mekinist in combination with dabrafenib is indicated for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with a braf v600 mutation and with no satisfactory locoregional treatment options.,non-small cell lung cancer (nsclc),mekinist in combination with dabrafenib is indicated for the treatment of patients with advanced non-small cell lung cancer (nsclc) with a braf v600 mutation.,low-grade glioma,mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy (see section 5.1 clinical studies).,high-grade glioma,mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with high-grade glioma (hgg) with a braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options (see section 5.1 clinical studies). .

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - trametinib dimethyl sulfoxide, quantity: 0.5635 mg (equivalent: trametinib, qty 0.5 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; iron oxide yellow; macrogol 400 - unresectable or metastatic melanoma,mekinist in combination with dabrafenib is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma.,mekinist as a monotherapy is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is intolerance to braf inhibitors or braf inhibitors cannot be used.,mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy (see section 5.1 clinical trials).,adjuvant treatment of melanoma,mekinist in combination with dabrafenib is indicated for the adjuvant treatment of patients with melanoma with a braf v600 mutation and involvement of the lymph node(s), following complete resection.,anaplastic thyroid cancer (atc),mekinist in combination with dabrafenib is indicated for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with a braf v600 mutation and with no satisfactory locoregional treatment options.,non-small cell lung cancer (nsclc),mekinist in combination with dabrafenib is indicated for the treatment of patients with advanced non-small cell lung cancer (nsclc) with a braf v600 mutation.,low-grade glioma,mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy (see section 5.1 clinical studies).,high-grade glioma,mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with high-grade glioma (hgg) with a braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options (see section 5.1 clinical studies).

קנדה - אנגלית - Health Canada

sandoz canada incorporated - dimethyl sulfoxide - solution - 500mg - dimethyl sulfoxide 500mg - miscellaneous therapeutic agents

אוסטרליה - אנגלית - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - dimethyl sulfoxide - topical cream, ointment, paste, gel, lotion - dimethyl sulfoxide solvent active 900.0 mg/g - musculoskeletal system - dog | horse | bitch | castrate | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at - analgesic | anti-inflammatory agent | antipyretic | bone soreness | bruising | bursitis | colic | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle relaxant | muscle soreness | osteoarthritis | platelet activity | rheumatism | sedative | spasmolytic | sprains | strains | tendon sprains | traumatic swelling

אוסטרליה - אנגלית - APVMA (Australian Pesticides and Veterinary Medicines Authority)

troy laboratories pty ltd - dimethyl sulfoxide - unknown - dimethyl sulfoxide solvent active 0.0 - active constituent

הממלכה המאוחדת - אנגלית - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - dimethyl sulfoxide - cream - 500mg/1gram

אוסטרליה - אנגלית - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - dimethyl sulfoxide - unknown - dimethyl sulfoxide solvent active 0.0 - active constituent

ארצות הברית - אנגלית - NLM (National Library of Medicine)

zoetis inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m), dimethyl sulfoxide (unii: yow8v9698h) (dimethyl sulfoxide - unii:yow8v9698h) - synotic otic solution veterinary is indicated for the relief of pruritus and inflammation associated with acute and chronic otitis in the dog.